title: [Interferon-inducible genes 2', 5'-ollgoadenylate synthetase-like and tetratricopeptide repeats 2 are correlated with clinical features of patients with systemic lupus erythematosus].
abstract: OBJECTIVE
  To investigate the expression levels of 2', 5'-oligoadenylate synthetase-like (OASL) and interferon induced protein with tetratricopeptide repeats 2 (IFIT2) genes in the peripheral blood leukocyte of patients with systemic lupus erythematosus (SLE), and to evaluate the relations between these gene expression levels and disease activity.
  
  
  METHODS
  The clinical data of 50 SLE patients, 25 non-SLE patients with rheumatic diseases, and 25 normal controls were collected. Specimens of peripheral blood were collected; total RNA was extracted and transcribed into cDNA. SYBR green dye based real-time quantitative PCR method was applied to compare the expression levels (indicated as deltaCT value) of OASL and IFIT2 in patients with SLE and those in the controls.
  
  
  RESULTS
  The deltaCT value of OASL expression level of the SLE patients was (4.83 +/- 0.41), significantly higher than those of the non-SLE patients (3.26 +/- 0.47) and normal controls (3.07 +/- 0.54, both P < 0.05), The deltaCT value of IFIT2 expression level of the SLE patients was (2.85 +/- 0.41), significantly higher than those of the non-SLE patients (1.19 +/- 0.52) and normal controls (1.07 +/- 0.47, both P < 0.05). The deltaCT value of OASL is related with the SLEDAI scores and immunoglobulin A. (Both P < 0.05). The deltaCT value of IFIT2 is related with the SLEDAI scores and IgA, white blood cell (both P < 0.05).
  
  
  CONCLUSIONS
  The value of IFIT2 and OASL expression level of the SLE patients is up-regulation, the real time expression levels of OASL and IFIT2 genes are associated with SLE disease activity. To inhibit the expression of OASL and IFIT2 may become a novel therapeutic approach for SLE.
authors.affiliation: Department of Rheumatology, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Zhen-yi
authors.initials: ZY
authors.lastname: Zhao
authors.forename: Nan-ping
authors.initials: NP
authors.lastname: Yang
authors.forename: Xiang-yang
authors.initials: XY
authors.lastname: Huang
authors.forename: Li
authors.initials: L
authors.lastname: Min
authors.forename: Xiao-xiao
authors.initials: XX
authors.lastname: Liu
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.forename: Yang
authors.initials: Y
authors.lastname: Ye
authors.forename: Lian-jie
authors.initials: LJ
authors.lastname: Shi
authors.forename: Xue
authors.initials: X
authors.lastname: Zhong
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood / Q000235:genetics*; D000328:Adult; D051017:Apoptosis Regulatory Proteins; D005260:Female; D006801:Humans; D007372:Interferons / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics; D016601:RNA-Binding Proteins; D055815:Young Adult
chemical_list: D051017:Apoptosis Regulatory Proteins; C484289:IFIT2 protein, human; D011506:Proteins; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D007372:Interferons; C115020:OASL protein, human; D015088:2',5'-Oligoadenylate Synthetase